ReviewBritish journal of cancer2022
Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications.
Review in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition.International journal of cancer · 2026Article
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Polycythemia Vera, Thrombophilia, CTEPH, Cerebral Venous Sinus Thrombosis and Vertebral Artery Occlusion: A Case-Illustrated Narrative Review of Competing Thrombotic and Hemorrhagic Risks.Life (Basel, Switzerland) · 2026Article
- Microfluidic Platforms for Modeling Cancer-Associated Thrombosis: Current Status and Future Directions.Research and practice in thrombosis and haemostasis · 2026Review
- Development and validation of a predictive model for perioperative venous thromboembolism in colorectal cancer patients based on D-dimer combined with fibrinogen levels.Translational cancer research · 2026Article
- Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer.Annals of surgical oncology · 2026Article
- Development of immunocompetent models for primary and metastatic ER+ breast cancer.Animal models and experimental medicine · 2026Article
- Mechanobiology of cancer-associated thrombosis: from molecular mechanisms to therapeutic innovation.Journal of nanobiotechnology · 2026Review
- Navigating the Hemostatic Balance: Anticoagulation and Antiplatelet Therapy in Patients with Thrombocytopenia.Journal of clinical medicine · 2026Review
- From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review.Cancers · 2026Review
- Pulmonary origin and risk assessment of cancer-associated thrombosis.Thrombosis journal · 2026Review
- Circulating tumor cells and circulating tumor microemboli: role in venous thromboembolism in oncologic patients.Bioscience reports · 2026Review
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Medical comorbidities prognosticate survival in glioblastoma.BJC reports · 2025Article
- Incidence and Predictors of Pulmonary Embolism Recurrence and Mortality in Patients With Lung Cancers.Cureus · 2025Article
- The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery.Blood advances · 2025Article
- Pulmonary Embolism in Acute Ischaemic Stroke: Evolving Evidence, Diagnostic Challenges, and a Novel Thromboinflammatory Axis Hypothesis.International journal of molecular sciences · 2025Review
- Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review.Journal of clinical medicine · 2025Review
- Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications.Thrombosis and haemostasis · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous and arterial thromboses, called as cancer-associated thromboembolism (CAT), are common complications in cancer patients that are associated with high mortality. The cell-surface glycoprotein tissue factor (TF) initiates the extrinsic blood coagulation cascade. TF is overexpressed in cancer cells and is a component of extracellular vesicles (EVs). Shedding of TF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.